The business of chemical bioanalysis was officially launched in 2015. With the entity operation in China and the United States, the company can support the bioanalysis business in China and abroad with high efficiency and quality. The company's small molecule bioanalysis business has rich experience in areas of high technical difficulty, such as inhalants, liposomes, high sensitivity, instability, endogenous drugs, peptide drugs, etc. At present, more than 1000 analytical methods have been established, including more than 380 chemical drug methods owned by the company. A total of more than 800 consistency evaluations and over 300 clinical sample analyses of small molecule chemical innovative drugs have been completed.（Data up to 2024.03.30）

Xihua is also equipped with special QC, QA, sample management and equipment management personnel in accordance with a certain proportion to support the efficient operation of biological analysis of chemical drugs.

Large molecule bioanalysis business, established in 2015, has a complete quality system, systemically verified instruments and electronic systems, and can provide clinical sample bioanalysis services that meet the requirements of Chinese and Western drug application. Xihua large molecule bioanalysis Group is mainly engaged in the biological analysis of clinical samples of monoclonal antibody, polyclonal antibody, ADC, fusion protein, peptide, gene therapy, vaccine, CAR T, heparin, coagulation factor and other types of drugs. It can support the detection of PK, ADA, Nab (combination assay and cell assay), biomarkers, in vivo efficacy, flow cytometry, ELISPOT, etc. In addition, in accordance with a certain proportion, Xihua is also equipped with additional personnel dedicated to chemical QC, QA, sample management and equipment management, to support the efficient operation of macromolecular biological analysis.

The company has accumulated more than 600 analysis methods, including more than 40 biological drug analysis methods with proprietary intellectual property rights, completed over 200 biological innovative drugs and biosimilar drug clinical trial sample analysis, completed biological analysis projects have more than 70 drugs approved for market.(Data up to 2024.03.30)
Xihua large molecule bioanalysis operates in both China and the United States, and can support the business in China and abroad with high efficiency and quality.